Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.

    Br J Urol 1998 Dec;82(6):933

    Similar Publications

    The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Clin Chem 1999 Nov;45(11):1960-6
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5.
    Background: Prostate-specific antigen (PSA) is the most reliable tumor marker available and is widely used for the diagnosis and management of prostate cancer. Unfortunately, PSA cannot distinguish efficiently between benign and malignant disease of the prostate, especially within the range of 4-10 microg/L. Among the refinements developed to enhance PSA specificity is the free/total PSA ratio, which is useful in discriminating between the two diseases within the diagnostic "gray zone". Read More
    Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
    J Urol 2002 Nov;168(5):1917-22
    Department of Urology, University of Hamburg Eppendorf, Germany.
    Purpose: Free prostate specific antigen (PSA) in serum consists of heterogeneous molecular subforms. Recently we developed an immunoassay for selective measurement of a subfraction of free PSA called intact PSA, which has been shown to be closely associated with prostate cancer. We assessed the ability of serum intact PSA to discriminate between benign and malignant prostatic disease. Read More
    [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Ned Tijdschr Geneeskd 1999 Aug;143(34):1733-8
    Martini Ziekenhuis, afd. Urologie, Groningen.
    Prostate specific antigen (PSA) is currently the tumour marker of choice for prostatic carcinoma. Various indices of PSA have been developed in an attempt to refine its sensitivity and improve its clinical value. These include the ratio of serum PSA level and prostate volume, the rate of change of the PSA level with time, age-referenced PSA, and the proportion of free PSA in serum relative to total PSA (free to total PSA ratio). Read More
    Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Anticancer Res 2001 Sep-Oct;21(5):3717-20
    Department of Clinical Biochemistry, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain.
    Background: The description of the different forms of circulating PSA has opened a new strategy in the diagnosis of prostate cancer. The aim of our study was to assess the diagnostic potential of PSA and the PSA fractions in the diagnosis of benign prostate hyperplasia (BPH) and prostate cancer.

    Patients And Methods: We measured the serum levels of PSA (Elecsys 2010, Roche Diagnostics, Mannheim, Germany), complexed PSA (Immuno 1 system, Bayer, Tarrytown, NY USA) and free PSA (Elecsys 2010, Roche Diagnostics, Mannheim, Germany) in 178 patients with BPH and 44 patients with prostate cancer. Read More